Biotech Stocks
Open Orphan Share Price Analysis: Transitioning to hVIVO plc
Looking for the Open Orphan share price? Discover how its rebrand to hVIVO plc (LSE: HVO) impacts its valuation, financial performance, and 2026 outlook.
ATHX Stock: The Rise, Fall, and Lessons of Athersys
Wondering what happened to ATHX stock? Here is the definitive guide to the bankruptcy of Athersys, the MultiStem trial failure, and key biotech lessons.
VTGN Stock Analysis: Is Vistagen a High-Risk Biotech Buy?
With the crucial PALISADE-4 trial readout looming in Q2 2026, find out if VTGN stock is a speculatively undervalued buy or a dangerous biotech trap.
ENZC Stock: SEC Settlement, Reverse Split, and Biotech Potential
Analyze ENZC stock risks and rewards. Explore Enzolytics' recent SEC settlement, the 500-to-1 reverse split, ITV-1 biotech pipeline, and Pink Sheet risks.
Moderna Share Price Analysis: 2026 Catalysts and Risks
Our expert Moderna share price analysis breaks down Q1 2026 earnings, pipeline progress with mCOMBRIAX and mRESVIA, and the Arbutus legal settlement.
VXRT Stock: Is Vaxart a Buy Ahead of Pivotal 2026 Catalysts?
Discover if Vaxart (VXRT stock) is a buy or sell in 2026. Get deep insights into clinical updates, the Dynavax deal, and OTCQX market performance.
TNXP Stock: Can Tonmya Sales Reverse the Dilution Cycle?
Tonix Pharmaceuticals (NASDAQ: TNXP) achieved FDA approval for Tonmya, but can commercial success outrun its dilutive history? Deep dive into TNXP stock.
CTXR Stock: Citius Pharmaceuticals 2026 Forecast & Pipeline Analysis
Is CTXR stock a buy? Get the ultimate Citius Pharmaceuticals analysis, covering Q2 2026 financial updates, the LYMPHIR launch, and the Mino-Lok pipeline.